140 related articles for article (PubMed ID: 35969004)
1. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena.
Borski A; Eskandary F; Haindl S; Doberer K; Mühlbacher J; Mayer KA; Budde K; Halloran PF; Chong E; Jilma B; Böhmig GA; Wahrmann M
Transplantation; 2023 Feb; 107(2):495-503. PubMed ID: 35969004
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K; Duerr M; Halloran PF; Eskandary F; Budde K; Regele H; Reeve J; Borski A; Kozakowski N; Reindl-Schwaighofer R; Waiser J; Lachmann N; Schranz S; Firbas C; Mühlbacher J; Gelbenegger G; Perkmann T; Wahrmann M; Kainz A; Ristl R; Halleck F; Bond G; Chong E; Jilma B; Böhmig GA
J Am Soc Nephrol; 2021 Mar; 32(3):708-722. PubMed ID: 33443079
[TBL] [Abstract][Full Text] [Related]
3. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.
Mühlbacher J; Schörgenhofer C; Doberer K; Dürr M; Budde K; Eskandary F; Mayer KA; Schranz S; Ely S; Reiter B; Chong E; Adler SH; Jilma B; Böhmig GA
Transpl Int; 2021 Aug; 34(8):1542-1552. PubMed ID: 34153143
[TBL] [Abstract][Full Text] [Related]
5. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Nickerson PW; Böhmig GA; Chadban S; Kumar D; Mannon RB; van Gelder T; Lee JC; Adler S; Chong E; Djamali A
Trials; 2022 Dec; 23(1):1042. PubMed ID: 36550562
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10.
Mayer KA; Doberer K; Halloran PF; Budde K; Haindl S; Mühlbacher J; Eskandary F; Viard T; Casas S; Jilma B; Böhmig GA
Transplant Direct; 2022 Dec; 8(12):e1406. PubMed ID: 36382130
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Mease PJ; Gottlieb AB; Berman A; Drescher E; Xing J; Wong R; Banerjee S
Arthritis Rheumatol; 2016 Sep; 68(9):2163-73. PubMed ID: 27059799
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.
Jordan SC; Ammerman N; Choi J; Huang E; Najjar R; Peng A; Sethi S; Sandhu R; Atienza J; Toyoda M; Ge S; Lim K; Gillespie M; Zhang X; Haas M; Vo A
Kidney Int Rep; 2022 Apr; 7(4):720-731. PubMed ID: 35497778
[TBL] [Abstract][Full Text] [Related]
9. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.
Vo AA; Huang E; Ammerman N; Toyoda M; Ge S; Haas M; Zhang X; Peng A; Najjar R; Williamson S; Myers C; Sethi S; Lim K; Choi J; Gillespie M; Tang J; Jordan SC
Am J Transplant; 2022 Apr; 22(4):1133-1144. PubMed ID: 34910841
[TBL] [Abstract][Full Text] [Related]
10. [Improving access to kidney transplantation for highly sensitized patients: What place for IL-6 pathway blockade in desensitization protocols?].
Weinhard J; Noble J; Jouve T; Malvezzi P; Rostaing L
Nephrol Ther; 2022 Dec; 18(7):577-583. PubMed ID: 36328901
[TBL] [Abstract][Full Text] [Related]
11. Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts.
Jordan SC; Ammerman N; Huang E; Vo A
Am J Transplant; 2022 Dec; 22 Suppl 4():28-37. PubMed ID: 36453709
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA; Budde K; Halloran PF; Doberer K; Rostaing L; Eskandary F; Christamentl A; Wahrmann M; Regele H; Schranz S; Ely S; Firbas C; Schörgenhofer C; Kainz A; Loupy A; Härtle S; Boxhammer R; Jilma B; Böhmig GA
Trials; 2022 Apr; 23(1):270. PubMed ID: 35395951
[TBL] [Abstract][Full Text] [Related]
13. IL-6 Directed Therapy in Transplantation.
Miller CL; Madsen JC
Curr Transplant Rep; 2021; 8(3):191-204. PubMed ID: 34099967
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
15. Anti-Interleukin 6 Therapeutics for Chronic Antibody-Mediated Rejection In Kidney Transplant Recipients.
Sharma R
Exp Clin Transplant; 2022 Aug; 20(8):709-716. PubMed ID: 34981708
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of mouse interleukin-17 bioactivity inhibits corneal allograft rejection.
Chen X; Zhao S; Tang X; Ge H; Liu P
Mol Vis; 2011; 17():2148-56. PubMed ID: 21850190
[TBL] [Abstract][Full Text] [Related]
20. New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment.
Mayer KA; Doberer K; Eskandary F; Halloran PF; Böhmig GA
Curr Opin Organ Transplant; 2021 Feb; 26(1):97-105. PubMed ID: 33315763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
